retatrutide news today recency 3 New Phase data just dropped 👀 Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Lilly's triple agonist, retatrutide, delivered

Read more about Nina's perspective on the brand reinvention, new app, GLP-1 direction, ChatGPT launch, fitness integration of The LIFTED Method and more here: #healthinnovation #weighthealth #WeightWatchers #branding #ChatGPT Describing where we are now as the GLP-1 era is sensible, as this medical breakthrough is definitely here to stay and certainly helpful in the short term

Cagrilintide: What the Evidence Actually Shows The pivotal standalone human dataset for cagrilintide is a multicentre, randomised, double-blind, placebo- and active-controlled, dose-finding Phase 2 trial in people with overweight or obesity

Variation in GLP1R, GIPR, and FTO relates to appetite signaling and body-weight regulation the same pathways any GLP-1-pathway compound engages

47.6% in the control group) [48]

The all-star option for GLP-1 users